Ocugen (OCGN) said Q2 delivered progress in its late-stage ophthalmology pipeline, including FDA clearance to start a Phase III study of OCU410 for geographic atrophy and an RMAT designation for the program. The FDA actions support faster potential development and regulatory engagement for OCU410, modestly improving the outlook for upcoming clinical milestones.
Ocugen (OCGN) said Q2 delivered progress in its late-stage ophthalmology pipeline, including FDA clearance to start a Phase III study of OCU410 for geographic atrophy and an RMAT designation for the program. The FDA actions support faster potential development and regulatory engagement for OCU410, modestly improving the outlook for upcoming clinical milestones.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
